446 related articles for article (PubMed ID: 27010943)
1. Economic Analysis of Prostate-Specific Antigen Screening and Selective Treatment Strategies.
Roth JA; Gulati R; Gore JL; Cooperberg MR; Etzioni R
JAMA Oncol; 2016 Jul; 2(7):890-8. PubMed ID: 27010943
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of prostate cancer screening: a simulation study based on ERSPC data.
Heijnsdijk EA; de Carvalho TM; Auvinen A; Zappa M; Nelen V; Kwiatkowski M; Villers A; Páez A; Moss SM; Tammela TL; Recker F; Denis L; Carlsson SV; Wever EM; Bangma CH; Schröder FH; Roobol MJ; Hugosson J; de Koning HJ
J Natl Cancer Inst; 2015 Jan; 107(1):366. PubMed ID: 25505238
[TBL] [Abstract][Full Text] [Related]
3. Comparative effectiveness of alternative prostate-specific antigen--based prostate cancer screening strategies: model estimates of potential benefits and harms.
Gulati R; Gore JL; Etzioni R
Ann Intern Med; 2013 Feb; 158(3):145-53. PubMed ID: 23381039
[TBL] [Abstract][Full Text] [Related]
4. A Cost-Utility Analysis of Prostate Cancer Screening in Australia.
Keller A; Gericke C; Whitty JA; Yaxley J; Kua B; Coughlin G; Gianduzzo T
Appl Health Econ Health Policy; 2017 Feb; 15(1):95-111. PubMed ID: 27757918
[TBL] [Abstract][Full Text] [Related]
5. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
Getaneh AM; Heijnsdijk EA; de Koning HJ
Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
[TBL] [Abstract][Full Text] [Related]
6. The cost-effectiveness of prostate cancer screening using the Stockholm3 test.
Karlsson AA; Hao S; Jauhiainen A; Elfström KM; Egevad L; Nordström T; Heintz E; Clements MS
PLoS One; 2021; 16(2):e0246674. PubMed ID: 33630863
[TBL] [Abstract][Full Text] [Related]
7. Estimating the harms and benefits of prostate cancer screening as used in common practice versus recommended good practice: A microsimulation screening analysis.
Carlsson SV; de Carvalho TM; Roobol MJ; Hugosson J; Auvinen A; Kwiatkowski M; Villers A; Zappa M; Nelen V; Páez A; Eastham JA; Lilja H; de Koning HJ; Vickers AJ; Heijnsdijk EA
Cancer; 2016 Nov; 122(21):3386-3393. PubMed ID: 27459245
[TBL] [Abstract][Full Text] [Related]
8. Is prostate cancer screening cost-effective? A microsimulation model of prostate-specific antigen-based screening for British Columbia, Canada.
Pataky R; Gulati R; Etzioni R; Black P; Chi KN; Coldman AJ; Pickles T; Tyldesley S; Peacock S
Int J Cancer; 2014 Aug; 135(4):939-47. PubMed ID: 24443367
[TBL] [Abstract][Full Text] [Related]
9. The prostate: decreasing cost-effectiveness of biopsy with advancing age.
Gottlieb RH; Mooney C; Mushlin AI; Rubens DJ; Fultz PJ
Invest Radiol; 1996 Feb; 31(2):84-90. PubMed ID: 8750443
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of magnetic resonance imaging and targeted fusion biopsy for early detection of prostate cancer.
Barnett CL; Davenport MS; Montgomery JS; Wei JT; Montie JE; Denton BT
BJU Int; 2018 Jul; 122(1):50-58. PubMed ID: 29388388
[TBL] [Abstract][Full Text] [Related]
11. The Cost-Effectiveness of Prostate Cancer Detection with the Use of Prostate Health Index.
Heijnsdijk EA; Denham D; de Koning HJ
Value Health; 2016; 19(2):153-7. PubMed ID: 27021748
[TBL] [Abstract][Full Text] [Related]
12. Comparative efficiency of prostate-specific antigen screening strategies for prostate cancer detection.
Ross KS; Carter HB; Pearson JD; Guess HA
JAMA; 2000 Sep; 284(11):1399-405. PubMed ID: 10989402
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness analysis of PSA-based mass screening: Evidence from a randomised controlled trial combined with register data.
Booth N; Rissanen P; Tammela TLJ; Kujala P; Stenman UH; Taari K; Talala K; Auvinen A
PLoS One; 2019; 14(11):e0224479. PubMed ID: 31689326
[TBL] [Abstract][Full Text] [Related]
14. Risk assessment to guide prostate cancer screening decisions: a cost-effectiveness analysis.
Martin AJ; Lord SJ; Verry HE; Stockler MR; Emery JD
Med J Aust; 2013 Jun; 198(10):546-50. PubMed ID: 23725269
[TBL] [Abstract][Full Text] [Related]
15. Polygenic risk-tailored screening for prostate cancer: A benefit-harm and cost-effectiveness modelling study.
Callender T; Emberton M; Morris S; Eeles R; Kote-Jarai Z; Pharoah PDP; Pashayan N
PLoS Med; 2019 Dec; 16(12):e1002998. PubMed ID: 31860675
[TBL] [Abstract][Full Text] [Related]
16. Active Surveillance Strategies for Low-Grade Prostate Cancer: Comparative Benefits and Cost-effectiveness.
Kang SK; Mali RD; Prabhu V; Ferket BS; Loeb S
Radiology; 2021 Sep; 300(3):594-604. PubMed ID: 34254851
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness of Annual Prostate MRI and Potential MRI-Guided Biopsy After Prostate-Specific Antigen Test Results.
Yun H; Kim J; Gandhe A; Nelson B; Hu JC; Gulani V; Margolis D; Schackman BR; Jalali A
JAMA Netw Open; 2023 Nov; 6(11):e2344856. PubMed ID: 38019516
[TBL] [Abstract][Full Text] [Related]
18. Benefit, Harm, and Cost-effectiveness Associated With Magnetic Resonance Imaging Before Biopsy in Age-based and Risk-stratified Screening for Prostate Cancer.
Callender T; Emberton M; Morris S; Pharoah PDP; Pashayan N
JAMA Netw Open; 2021 Mar; 4(3):e2037657. PubMed ID: 33704474
[TBL] [Abstract][Full Text] [Related]
19. Economic evaluation of prostate cancer screening with prostate-specific antigen.
Imamura T; Yasunaga H
Int J Urol; 2008 Apr; 15(4):285-8. PubMed ID: 18380812
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of percent free PSA for prostate cancer detection in men with a total PSA of 4-10 ng/ml.
Bermúdez-Tamayo C; Martín Martín JJ; González Mdel P; Pérez Romero C
Urol Int; 2007; 79(4):336-44. PubMed ID: 18025853
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]